Terms: = Endocrine gland cancer AND LPP, Q93052, 4026, ENSG00000145012 AND Treatment
4 results:
1. LINC00092 Enhances lpp Expression to Repress Thyroid cancer Development via Sponging miR-542-3p.
Wang H
Horm Metab Res; 2024 Feb; 56(2):150-158. PubMed ID: 37935247
[TBL] [Abstract] [Full Text] [Related]
2. Case Report: Identification of Potential Prognosis-Related
Zhang Y; Ma L; Liu J; Zhu H; Lu L; Deng K; Ma W; Pan H; Wang R; Yao Y
Front Endocrinol (Lausanne); 2021; 12():673908. PubMed ID: 34381423
[TBL] [Abstract] [Full Text] [Related]
3. [Lysophosphatidic acid as a potential target for treatment and molecular diagnosis of epithelial ovarian cancers].
Tanyi J; Rigó J
Orv Hetil; 2009 Jun; 150(24):1109-18. PubMed ID: 19739275
[TBL] [Abstract] [Full Text] [Related]
4. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
[TBL] [Abstract] [Full Text] [Related]
